Serial Ultrasound to Detect Early Response to Immunotherapy in Metastatic RCC

连续超声检测转移性肾细胞癌免疫治疗的早期反应

基本信息

  • 批准号:
    10357118
  • 负责人:
  • 金额:
    $ 18.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-09 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Project Summary We propose a pilot study to detect response to immunotherapy as early as 3 weeks after initiating therapy, using Doppler ultrasound and contrast-enhanced ultrasound (CEUS) to measure changes in tumor vascularity in patients with metastatic renal cell carcinoma (mRCC). Biomarkers to rapidly detect response to RCC therapy are urgently needed, because not all patients respond to first-line treatment with combined CTLA-4 immune checkpoint inhibitor (ipilimumab) plus anti-PD-1 immune checkpoint inhibitor (nivolumab). Yet, all patients endure the side effects of this combination treatment (fatigue, autoimmune hepatitis/thyroiditis/pneumonitis etc.) while awaiting standard-of-care computed tomography (CT) imaging. Currently, 12 weeks is required to assess response by measuring decreases in tumor diameters with CT because tumor size does not significantly change before 12 weeks of therapy. Rapid detection of response to RCC therapy would minimize use of ineffective drugs and allow patients to discontinue ineffective therapies and continue only effective therapy. We have found that imaging-based measurements of tumor vascularity, such as perfusion CT scans, can detect early response to therapy in mRCC. But these require potentially nephrotoxic iodine contrast agents and visits to the radiology department. We have developed highly sensitive, non-contrast, vascular imaging using advanced power Doppler ultrasound that can be performed at bedside in the oncology clinic to image vessels as small as 1 mm in diameter. Now, we propose to use advanced power Doppler ultrasound for a pilot study to assess changes in tumor vascularity, during routine oncology clinic visits for patients receiving combined therapy, and compare it to conventional power Doppler and contrast-enhanced ultrasound (CEUS, using non-nephrotoxic micro-/nanobubble contrast agents). We hypothesize that changes in tumor vascularity, measured by ultrasound, can detect response to treatment earlier than changes in tumor diameters. We will enroll 30 patients with mRCC, to be evaluated with Doppler ultrasound and CEUS before treatment and after 3 weeks and 6 weeks of combined ipilimumab and nivolumab therapy. Our pilot study aims to determine if 1) Doppler ultrasound and/or CEUS can detect changes as early as 3 and/or 6 weeks after initiating immunotherapy; 2) if changes detected by ultrasound correlate with response measured by standard- of-care CT scan after 12 weeks of therapy; and 3) which ultrasound time point (3 weeks or 6 weeks) better anticipates 12-week results. We will use ultrasound imaging to accelerate detection of response to combined ipilimumab + nivolumab. If successful, we can apply our approach to additional tumors and drugs, as changes in tumor vascularity are a key mechanism of response to most cancer therapies.
项目摘要 我们建议进行一项试点研究,以检测免疫治疗后3周内的反应, 治疗,使用多普勒超声和对比增强超声(CEUS)来测量 转移性肾细胞癌(mRCC)患者的肿瘤血管分布。快速检测的生物标志物 对RCC治疗的反应是迫切需要的,因为并非所有患者都对一线治疗有反应, 联合CTLA-4免疫检查点抑制剂(伊匹单抗)+抗PD-1免疫检查点抑制剂 (纳武单抗)。然而,所有患者都忍受这种联合治疗的副作用(疲劳、自身免疫性 肝炎/甲状腺炎/肺炎等)同时等待标准护理计算机断层扫描(CT)成像。 目前,需要12周通过CT测量肿瘤直径的减小来评估反应, 肿瘤大小在12周治疗前没有显著变化。快速检测对RCC治疗的反应 将最大限度地减少无效药物的使用,并允许患者停止无效治疗, 有效的治疗。我们发现,基于成像的肿瘤血管测量,如灌注CT, 扫描,可以检测早期反应的治疗mRCC。但这些需要潜在的肾毒性碘造影剂 代理人和访问放射科。我们已经开发出了高灵敏度,非造影,血管 使用先进的能量多普勒超声成像,可以在肿瘤诊所的床边进行, 成像直径小至1 mm的血管。现在,我们建议使用先进的功率多普勒超声, 一项初步研究,旨在评估接受以下治疗的患者在常规肿瘤学门诊访视期间肿瘤血管分布的变化: 联合治疗,并将其与传统的能量多普勒和对比增强超声(CEUS, 使用非肾毒性的微泡/纳米泡造影剂)。我们假设肿瘤的变化 通过超声测量的血管分布可以比肿瘤变化更早地检测到对治疗的反应。 直径。我们将招募30例mRCC患者,在术前进行多普勒超声和CEUS评估, 治疗后以及在伊匹单抗和纳武单抗组合治疗3周和6周后。我们的试点研究旨在 以确定1)多普勒超声和/或CEUS是否可以在术后3周和/或6周检测到变化 启动免疫疗法; 2)如果通过超声检测到的变化与通过标准- 治疗12周后的出院CT扫描;以及3)哪个超声时间点(3周或6周)更好 预计12周的结果。我们将使用超声波成像来加速检测反应, 联合伊匹单抗+纳武单抗。如果成功,我们可以将我们的方法应用于其他肿瘤和药物, 因为肿瘤血管分布的变化是对大多数癌症治疗反应的关键机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeremy Dahl其他文献

Jeremy Dahl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeremy Dahl', 18)}}的其他基金

B7-H3 Targeted Ultrasound Molecular Imaging System for Early Breast Cancer and Metastatic Detection
B7-H3 用于早期乳腺癌和转移检测的靶向超声分子成像系统
  • 批准号:
    10584161
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
Serial Ultrasound to Detect Early Response to Immunotherapy in Metastatic RCC
连续超声检测转移性肾细胞癌免疫治疗的早期反应
  • 批准号:
    10589070
  • 财政年份:
    2022
  • 资助金额:
    $ 18.09万
  • 项目类别:
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
提高难以成像患者的肝脏超声图像质量
  • 批准号:
    10410471
  • 财政年份:
    2020
  • 资助金额:
    $ 18.09万
  • 项目类别:
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
提高难以成像患者的肝脏超声图像质量
  • 批准号:
    9885175
  • 财政年份:
    2020
  • 资助金额:
    $ 18.09万
  • 项目类别:
Early therapeutic monitoring of response to therapy with serial ultrasound in metastatic RCC
转移性肾细胞癌连续超声治疗反应的早期治疗监测
  • 批准号:
    10046819
  • 财政年份:
    2020
  • 资助金额:
    $ 18.09万
  • 项目类别:
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
提高难以成像患者的肝脏超声图像质量
  • 批准号:
    10634660
  • 财政年份:
    2020
  • 资助金额:
    $ 18.09万
  • 项目类别:
Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug Delivery
使用超声引导药物输送对肝细胞癌进行治疗性 miRNA 调节
  • 批准号:
    9299022
  • 财政年份:
    2017
  • 资助金额:
    $ 18.09万
  • 项目类别:
Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug Delivery
使用超声引导药物输送对肝细胞癌进行治疗性 miRNA 调节
  • 批准号:
    9893823
  • 财政年份:
    2017
  • 资助金额:
    $ 18.09万
  • 项目类别:
High Sensitivity Molecular Ultrasound Imaging in Pancreatic Cancer
胰腺癌的高灵敏度分子超声成像
  • 批准号:
    9302759
  • 财政年份:
    2016
  • 资助金额:
    $ 18.09万
  • 项目类别:
High Sensitivity Flow Imaging of the Human Placenta with Coherence-Based Doppler Ultrasound
使用相干多普勒超声对人胎盘进行高灵敏度血流成像
  • 批准号:
    9270591
  • 财政年份:
    2015
  • 资助金额:
    $ 18.09万
  • 项目类别:

相似海外基金

Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
  • 批准号:
    EP/Y031091/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.09万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.09万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
    Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
  • 批准号:
    10715807
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
  • 批准号:
    MR/Y003667/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
    Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
Sjogren's Syndrome Pathogenic Autoantibodies
干燥综合征致病性自身抗体
  • 批准号:
    10854472
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 18.09万
  • 项目类别:
    Operating Grants
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
  • 批准号:
    10481071
  • 财政年份:
    2022
  • 资助金额:
    $ 18.09万
  • 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10526475
  • 财政年份:
    2022
  • 资助金额:
    $ 18.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了